Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study
Objective Although central serous chorioretinopathy (CSC) treatment using selective retinal therapy (SRT) has presented favourable outcomes, no long-term studies with a real-world clinical practice regimen have been conducted.Methods and analysis We performed a long-term assessment of CSC treatment...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-05-01
|
| Series: | BMJ Open Ophthalmology |
| Online Access: | https://bmjophth.bmj.com/content/9/1/e001517.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832086571768086528 |
|---|---|
| author | Hyeong Gon Yu Chang Ki Yoon |
| author_facet | Hyeong Gon Yu Chang Ki Yoon |
| author_sort | Hyeong Gon Yu |
| collection | DOAJ |
| description | Objective Although central serous chorioretinopathy (CSC) treatment using selective retinal therapy (SRT) has presented favourable outcomes, no long-term studies with a real-world clinical practice regimen have been conducted.Methods and analysis We performed a long-term assessment of CSC treatment using SRT with real-time feedback (RTF) technology. 50 patients (53 eyes) with CSC and more than a 1-month symptom duration were recruited and treated with SRT using a 1.7 µs pulse width, 527 nm neodymium-doped yttrium lithium fluoride (Nd:YLF) laser equipped with an RTF system.Results After 6 months of treatment, complete subretinal fluid resolution was achieved in 62% of the eyes. The mean best-corrected visual acuity (BCVA; logarithm of the minimum angle of resolution, mean±SD) improved slightly from 0.15±0.18 at baseline to 0.12±0.21 at 6 months (p=0.062). The central retinal thickness (CRT; mean±SD) was reduced significantly from 350.6±100.1 µm at baseline to 268.2±70.6 µm at 6 months (p<0.001). Long-term follow-up revealed significant improvements in BCVA, from 9 months until 24 months, and in CRT, from 1 month until 24 months. No treatment-related adverse events were observed during the 24-month follow-up period.Conclusion Our results suggest that SRT with RTF technology is a long-term safe treatment with anatomical improvement for patients with CSC. |
| format | Article |
| id | doaj-art-564be7ed873f4e068c48724f4e80b55f |
| institution | Kabale University |
| issn | 2397-3269 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Ophthalmology |
| spelling | doaj-art-564be7ed873f4e068c48724f4e80b55f2025-02-06T11:35:11ZengBMJ Publishing GroupBMJ Open Ophthalmology2397-32692024-05-019110.1136/bmjophth-2023-001517Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective studyHyeong Gon Yu0Chang Ki Yoon1Collaborator (non-author)Department of Ophthalmology, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)Objective Although central serous chorioretinopathy (CSC) treatment using selective retinal therapy (SRT) has presented favourable outcomes, no long-term studies with a real-world clinical practice regimen have been conducted.Methods and analysis We performed a long-term assessment of CSC treatment using SRT with real-time feedback (RTF) technology. 50 patients (53 eyes) with CSC and more than a 1-month symptom duration were recruited and treated with SRT using a 1.7 µs pulse width, 527 nm neodymium-doped yttrium lithium fluoride (Nd:YLF) laser equipped with an RTF system.Results After 6 months of treatment, complete subretinal fluid resolution was achieved in 62% of the eyes. The mean best-corrected visual acuity (BCVA; logarithm of the minimum angle of resolution, mean±SD) improved slightly from 0.15±0.18 at baseline to 0.12±0.21 at 6 months (p=0.062). The central retinal thickness (CRT; mean±SD) was reduced significantly from 350.6±100.1 µm at baseline to 268.2±70.6 µm at 6 months (p<0.001). Long-term follow-up revealed significant improvements in BCVA, from 9 months until 24 months, and in CRT, from 1 month until 24 months. No treatment-related adverse events were observed during the 24-month follow-up period.Conclusion Our results suggest that SRT with RTF technology is a long-term safe treatment with anatomical improvement for patients with CSC.https://bmjophth.bmj.com/content/9/1/e001517.full |
| spellingShingle | Hyeong Gon Yu Chang Ki Yoon Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study BMJ Open Ophthalmology |
| title | Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study |
| title_full | Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study |
| title_fullStr | Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study |
| title_full_unstemmed | Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study |
| title_short | Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study |
| title_sort | selective retina therapy with real time feedback controlled technology in central serous chorioretinopathy a 24 month follow up real world prospective study |
| url | https://bmjophth.bmj.com/content/9/1/e001517.full |
| work_keys_str_mv | AT hyeonggonyu selectiveretinatherapywithrealtimefeedbackcontrolledtechnologyincentralserouschorioretinopathya24monthfollowuprealworldprospectivestudy AT changkiyoon selectiveretinatherapywithrealtimefeedbackcontrolledtechnologyincentralserouschorioretinopathya24monthfollowuprealworldprospectivestudy |